Chronic myelomonocytic leukaemia (CMML) is a morphological hybrid between myelodysplastic and myeloproliferative neoplasms and is characterized by clonal monocytosis. Myeloid neoplasm-associated somatic mutations are present in >90% of patients with CMML but are not diagnostically specific but a subset are prognostically relevant. Current drug therapy in CMML is mostly palliative and not disease-modifying. Allogeneic haematopoietic stem cell transplantation is a potentially curative treatment modality in CMML and its timing is determined by formal prognostic models including the recently developed BLAST and BLAST-molecular risk models.
{"title":"Chronic myelomonocytic leukaemia","authors":"Ayalew Tefferi, Mrinal M. Patnaik","doi":"10.1111/bjh.70226","DOIUrl":"10.1111/bjh.70226","url":null,"abstract":"<div>\u0000 \u0000 <p>Chronic myelomonocytic leukaemia (CMML) is a morphological hybrid between myelodysplastic and myeloproliferative neoplasms and is characterized by clonal monocytosis. Myeloid neoplasm-associated somatic mutations are present in >90% of patients with CMML but are not diagnostically specific but a subset are prognostically relevant. Current drug therapy in CMML is mostly palliative and not disease-modifying. Allogeneic haematopoietic stem cell transplantation is a potentially curative treatment modality in CMML and its timing is determined by formal prognostic models including the recently developed BLAST and BLAST-molecular risk models.</p>\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"207 6","pages":"2280-2282"},"PeriodicalIF":3.8,"publicationDate":"2025-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145429845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Izidore S Lossos, Juliette L Martin, Jennifer R Chapman, Georgios N Pongas
{"title":"Peripheral blood involvement in extra-nodal marginal zone lymphoma.","authors":"Izidore S Lossos, Juliette L Martin, Jennifer R Chapman, Georgios N Pongas","doi":"10.1111/bjh.70232","DOIUrl":"https://doi.org/10.1111/bjh.70232","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145407669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Max J Gordon, Rahul Lakhotia, Stefania Pittaluga, Svetlana D Pack, Anna Marie Juanitez, Ahmed Hamdy, Amy J Johnson, Melanie M Frigault, Raquel Izumi, Mark Raffeld, Mark Roschewski, Wyndham H Wilson, Christopher Melani
{"title":"Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphoma.","authors":"Max J Gordon, Rahul Lakhotia, Stefania Pittaluga, Svetlana D Pack, Anna Marie Juanitez, Ahmed Hamdy, Amy J Johnson, Melanie M Frigault, Raquel Izumi, Mark Raffeld, Mark Roschewski, Wyndham H Wilson, Christopher Melani","doi":"10.1111/bjh.70234","DOIUrl":"https://doi.org/10.1111/bjh.70234","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145407654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To evaluate the efficacy and safety of the HAAV regimen (venetoclax, aclarubicin, cytarabine, homoharringtonine) as induction therapy for newly diagnosed adult acute myeloid leukaemia (AML). This multicentre, single-arm, prospective clinical trial included 84 AML patients (aged 18-60) from eight Chinese hospitals. The HAAV regimen was administered, with venetoclax dosed at 100 mg on day 1, 200 mg on day 2 and 400 mg on days 3-8, combined with homoharringtonine, cytarabine and aclarubicin on days 3-7. The overall response rate after one cycle was 95.2% (95% confidence interval [CI] 88.3-98.7), with 92.9% achieving complete remission + incomplete count recovery (95% CI 83.6-96.6). Among responders, 89.9% (95% CI 80.2-95.8) had minimal residual disease negativity. With a median follow-up of 15.5 months, the -1-year overall survival was 77.9% (95% CI 18.3-26.1), relapse-free survival was 83.9% (95% CI 19.2-22.3) and event-free survival was 71.3% (95% CI 16.9-20.5). The HAAV regimen is highly efficacious and safe for newly diagnosed AML patients.
评估HAAV方案（venetoclax、阿克鲁比星、阿糖胞苷、高杉碱）作为诱导治疗新诊断的成人急性髓性白血病（AML）的有效性和安全性。这项多中心、单臂、前瞻性临床试验包括来自中国8家医院的84例AML患者（18-60岁）。给予HAAV方案，venetoclax剂量为100 mg（第1200天），200 mg（第2天），400 mg（第3-8天），联合高杉碱、阿糖胞苷和阿克拉比星（第3-7天）。一个周期后的总有效率为95.2%(95%可信区间[CI] 88.3-98.7)，其中92.9%达到完全缓解+计数不完全恢复（95% CI 83.6-96.6）。在应答者中，89.9% （95% CI 80.2-95.8）有最小残留疾病阴性反应。中位随访15.5个月，1年总生存率为77.9% (95% CI 18.3-26.1)，无复发生存率为83.9% (95% CI 19.2-22.3)，无事件生存率为71.3% （95% CI 16.9-20.5）。HAAV方案对新诊断的AML患者是非常有效和安全的。
{"title":"Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study.","authors":"Yaxian Tan, Xingli Zhao, Xiaohui Suo, Guanchen Bai, Weihua Zhao, Yunya Luo, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Zeyan Shi, Heng Li, Kaiqi Liu, Yingchang Mi, Hongling Peng, Pengxiang Guo, Zeping Zhou","doi":"10.1111/bjh.70202","DOIUrl":"https://doi.org/10.1111/bjh.70202","url":null,"abstract":"<p><p>To evaluate the efficacy and safety of the HAAV regimen (venetoclax, aclarubicin, cytarabine, homoharringtonine) as induction therapy for newly diagnosed adult acute myeloid leukaemia (AML). This multicentre, single-arm, prospective clinical trial included 84 AML patients (aged 18-60) from eight Chinese hospitals. The HAAV regimen was administered, with venetoclax dosed at 100 mg on day 1, 200 mg on day 2 and 400 mg on days 3-8, combined with homoharringtonine, cytarabine and aclarubicin on days 3-7. The overall response rate after one cycle was 95.2% (95% confidence interval [CI] 88.3-98.7), with 92.9% achieving complete remission + incomplete count recovery (95% CI 83.6-96.6). Among responders, 89.9% (95% CI 80.2-95.8) had minimal residual disease negativity. With a median follow-up of 15.5 months, the -1-year overall survival was 77.9% (95% CI 18.3-26.1), relapse-free survival was 83.9% (95% CI 19.2-22.3) and event-free survival was 71.3% (95% CI 16.9-20.5). The HAAV regimen is highly efficacious and safe for newly diagnosed AML patients.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Peter Brændstrup, Thomas Bech Mortensen, Tarec Christoffer El-Galaly, Michael Boe Møller, Judit Mészáros Jørgensen, Christian Bjørn Poulsen, Michael Roost-Clausen, Peter de Nully Brown, Dennis Lund Hansen, Thomas Stauffer Larsen
{"title":"Outcome of T-cell/histiocyte-rich large B-cell lymphoma—A Danish nationwide matched cohort study","authors":"Peter Brændstrup, Thomas Bech Mortensen, Tarec Christoffer El-Galaly, Michael Boe Møller, Judit Mészáros Jørgensen, Christian Bjørn Poulsen, Michael Roost-Clausen, Peter de Nully Brown, Dennis Lund Hansen, Thomas Stauffer Larsen","doi":"10.1111/bjh.70217","DOIUrl":"10.1111/bjh.70217","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"207 6","pages":"2574-2577"},"PeriodicalIF":3.8,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ping Zou Stinnett, Robert J Ogg, Kathleen Helton, Winfred Wang, Andrew M Heitzer, Zachary Abramson, Yimei Li, Tushar Patni, Paul VanGilder, Akshay Sharma, Ranganatha Sitaram
Opposite to the age trend in healthy children, cerebral blood flow increases with age in children with sickle cell anaemia. Early treatment with hydroxyurea (hydroxycarbamide) may help slow this abnormal trend and protect brain functions.
{"title":"Cerebral blood flow trajectories in paediatric sickle cell anaemia by age, region, and treatment associations.","authors":"Ping Zou Stinnett, Robert J Ogg, Kathleen Helton, Winfred Wang, Andrew M Heitzer, Zachary Abramson, Yimei Li, Tushar Patni, Paul VanGilder, Akshay Sharma, Ranganatha Sitaram","doi":"10.1111/bjh.70224","DOIUrl":"https://doi.org/10.1111/bjh.70224","url":null,"abstract":"<p><p>Opposite to the age trend in healthy children, cerebral blood flow increases with age in children with sickle cell anaemia. Early treatment with hydroxyurea (hydroxycarbamide) may help slow this abnormal trend and protect brain functions.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Khaled M Musallam, Ali T Taher, John B Porter, Antonis Kattamis, Mrudula B Glassberg, Luciana Moro Bueno, Patricia Martin-Regueira, Marta Reverte, Loyse Felber Medlin, Matthew Dyer, Kefeng Wang, Maria Domenica Cappellini
In this post hoc analysis of the phase 2 BEYOND trial, the majority of patients with non-transfusion-dependent β-thalassaemia achieved clinically meaningful haemoglobin levels ≥10.0 g/dL and increases from baseline ≥1.0 g/dL, thresholds associated with reduced risk of morbidity and mortality and recommended as an indication and target for treatment by international management guidelines, respectively.
{"title":"Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial.","authors":"Khaled M Musallam, Ali T Taher, John B Porter, Antonis Kattamis, Mrudula B Glassberg, Luciana Moro Bueno, Patricia Martin-Regueira, Marta Reverte, Loyse Felber Medlin, Matthew Dyer, Kefeng Wang, Maria Domenica Cappellini","doi":"10.1111/bjh.70227","DOIUrl":"https://doi.org/10.1111/bjh.70227","url":null,"abstract":"<p><p>In this post hoc analysis of the phase 2 BEYOND trial, the majority of patients with non-transfusion-dependent β-thalassaemia achieved clinically meaningful haemoglobin levels ≥10.0 g/dL and increases from baseline ≥1.0 g/dL, thresholds associated with reduced risk of morbidity and mortality and recommended as an indication and target for treatment by international management guidelines, respectively.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145372151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号